Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

830 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Novel Method of Calculating the Drained Liver Volume Using a 3D Volume Analyzer for Biliary Drainage of Unresectable Malignant Hilar Biliary Obstruction.
Imagawa N, Fukasawa M, Takano S, Kawakami S, Fukasawa Y, Hasegawa H, Kuratomi N, Harai S, Shimamura N, Yoshimura D, Kobayashi S, Yoshida T, Sato M, Suzuki Y, Enomoto N. Imagawa N, et al. Among authors: enomoto n. Dig Dis Sci. 2024 Mar;69(3):969-977. doi: 10.1007/s10620-024-08294-z. Epub 2024 Feb 1. Dig Dis Sci. 2024. PMID: 38300418 Free PMC article. Review.
Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
Suzuki Y, Maekawa S, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Takada H, Muraoka M, Sato M, Takano S, Fukasawa M, Yamaguchi T, Funayama S, Morisaka H, Onishi H, Enomoto N. Suzuki Y, et al. Among authors: enomoto n. J Gastroenterol Hepatol. 2023 Jun;38(6):921-929. doi: 10.1111/jgh.16154. Epub 2023 Mar 5. J Gastroenterol Hepatol. 2023. PMID: 36811251
Comparison of 6-mm and 10-mm-diameter, fully-covered, self-expandable metallic stents for distal malignant biliary obstruction.
Harai S, Hijioka S, Nagashio Y, Ohba A, Maruki Y, Yamashige D, Hisada Y, Yoshinari M, Kitamura H, Maehara K, Murashima Y, Kawasaki Y, Koga T, Takeshita K, Ueno H, Kondo S, Morizane C, Fukasawa M, Sone M, Saito Y, Enomoto N, Okusaka T. Harai S, et al. Among authors: enomoto n. Endosc Int Open. 2023 Apr 17;11(4):E340-E348. doi: 10.1055/a-2039-4316. eCollection 2023 Apr. Endosc Int Open. 2023. PMID: 37077662 Free PMC article.
Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Takano S, Fukasawa M, Yamaguchi T, Maekawa S, Takahashi K, Uchimura K, Enomoto N. Takada H, et al. Among authors: enomoto n. Oncology. 2023;101(10):609-623. doi: 10.1159/000531111. Epub 2023 Jun 6. Oncology. 2023. PMID: 37279708
Significance of the autoantibody assay in predicting the development of immune-related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Muraoka M, Suzuki Y, Sato M, Kobayashi S, Yoshida T, Takano S, Maekawa S, Enomoto N. Takada H, et al. Among authors: enomoto n. Hepatol Res. 2024 Feb;54(2):162-173. doi: 10.1111/hepr.13969. Epub 2023 Oct 6. Hepatol Res. 2024. PMID: 37740643
830 results